GW-1516

GW-501516 (also known as GW-501, 516, GW1516, GW-1516 or GSK-516) is an agonist of PPAR-delta receptor. It activates the body's mechanisms operating during exercise, including PPARdelta and 5'AMF-activated protein kinase. GW-501516 investigated as a potential treatment for obesity, diabetes, dyslipidemia, and cardiovascular diseases. GW-501516 in combination with AICAR have a synergistic effect: in animal studies it has been shown that this combination provides a much greater increase in stamina during exercise than using each of the compounds individually.

GW-156 regulates fat burning through a number of mechanisms: an increase in glucose uptake in skeletal muscle tissues, increased expression of genes, particularly genes involved in the preferential use of lipids. Activation of these mechanisms alters the body's metabolism in favor of burning fat for energy it is, rather than carbohydrates or muscle proteins. GW-50156 can be used by people suffering from obesity, for effective fat loss, without muscle catabolism or decrease in blood sugar levels. GW-1516 and increases muscle mass and improves glucose tolerance and even reduces fat accumulation in mice consume food with a very high fat content. Thus, GW-501516 has a protective effect against obesity.
When administered orally GW-1516 at doses 10 mg daily treatment was found metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, which is likely due to the observed stimulation of fatty acid oxidation. In addition, there was a 79% increase in HDL cholesterol levels in Rhesus monkeys. The present compound is tested phase II, where its effect is considered to increase the level of "good" cholesterol (HDL) in the body. Please pay attention to Chelohart.

Even before the Beijing Olympics 2008, representatives of regulatory bodies have expressed concern that GW-1516 can be used by athletes as a performance-enhancing drugs, which at that time was controlled by any rule, and could not be detected by standard tests. One of the main Olympic Committee of experts on research to increase endurance engaged in development of a urine test to detect the presence of the drug in the body. World Anti-Doping Agency also began working on a test for the detection of GW-501516 and other related PPAR-delta modulators, and since 2009, these substances have been added to the list of prohibited drugs. Compound still not controlled or banned in any country of the world. Today it is known that when assays athlete none of the substance has not been found, despite the fact that the increase in endurance performance of muscle fibers, fat mass loss and metabolism offers great potential for use and abuse ergogenic GW-501516.